Full Text Journal Articles in
Journal Clin Cancer Res

Advertisement

Find full text journal articles






The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.

Shwetha H Manjunath, Adam D Cohen, Simon F Lacey, Megan M Davis, Alfred L Garfall, J Joseph Melenhorst, Russell Maxwell, William Tristram Arscott, Amit Maity, Joshua A Jones, John P Plastaras, Edward A Stadtmauer, Bruce L Levine, Carl H June, Michael C Milone, Ima Paydar,

<h4>Purpose</h4>B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cells (CART-BCMA) are a promising treatment for relapsed/refractory multiple myeloma (r/rMM). We evaluated the safety and feasibility of bridging radiation (RT) in subjects treated on a phase 1 trial of CART-BCMA.<h4>Experimental design</h4>Twenty-five r/rMM subjects were treated in 3 cohorts with two doses ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses.

Denise L Cecil, John B Liao, Yushe Dang, Andrew L Coveler, Angela Kask, Yi Yang, Jennifer Childs, Doreen Higgins, Mary L Disis,

<h4>Background</h4>Cancer vaccines targeting nonmutated proteins elicit limited Type I T-cell responses and can generate T-regulatory and Type II T-cells. Class II epitopes that selectively elicit Type I or Type II cytokines can be identified in nonmutated cancer associated proteins. In mice, a T-helper I selective IGFBP-2 N-terminus vaccine generated high ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial.

Costanza Paoletti, William E Barlow, Erin F Cobain, Mattias Bergqvist, Rita S Mehta, Julie R Gralow, Gabriel N Hortobagyi, Kathy S Albain, Lajos Pusztai, Priyanka Sharma, Andrew K Godwin, Alastair M Thompson, Daniel F Hayes, James M Rae,

<h4>Purpose</h4>Serum Thymidine Kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) vs. A plus fulvestrant (A+F).<h4>Experimental design</h4>sTK1 was assessed in 1,726 serums [baseline ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.

Angelo Porciuncula, Micaela Morgado, Richa Gupta, Kostas Syrigos, Robert Meehan, Sima J Zacharek, Joshua P Frederick, Kurt A Schalper,

<h4>Purpose</h4>To evaluate the tissue distribution and clinical significance of OX40 and OX40L in human non-small cell lung cancer (NSCLC).<h4>Experimental design</h4>Using multiplexed quantitative immunofluorescence (QIF), we conducted simultaneous and localized measurements of OX40 and OX40L proteins, major T-cell subsets and conventional type-1 dendritic cells (cDC1) in 614 primary NSCLCs from three ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



DIAGNOSTIC ACCURACY OF FEC-PET/CT, FDG-PET/CT AND DIFFUSION-WEIGHTED MRI IN DETECTION OF NODAL METASTASES IN SURGICALLY TREATED ENDOMETRIAL AND CERVICAL CARCINOMA.

Andrea G Rockall, Tara D Barwick, William Wilson, Naveena Singh, Nishat Bharwani, Aslam Sohaib, Marielle Nobbenhuis, Victoria Warbey, Marc Miquel, Dow-Mu Koh, Katja N De Paepe, Pierre Martin-Hirsch, Sadaf Ghaem-Maghami, Christina Fotopoulou, Helen Stringfellow, Sudha Sundar, Ranjit Manchanda, Anju Sahdev, Allan Hackshaw, Gary J Cook, Mapping Study Group,

<h4>Purpose</h4>Pre-operative nodal staging is important for planning treatment in cervical cancer (CC) and endometrial cancer (EC) but remains challenging. We compare nodal staging accuracy of <sup>18</sup>F-ethyl-choline-(FEC)-PET/CT, <sup>18</sup>F-Fluoro-deoxy-glucose-(FDG)-PET/CT and diffusion-weighted-MRI (DW-MRI) with conventional morphological MRI.<h4>Experimental design</h4>A prospective, multicentre observational study of diagnostic accuracy for nodal metastases was undertaken in 5 gyne-oncology ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Functional impact of genomic complexity on the transcriptome of Multiple Myeloma.

Bachisio Ziccheddu, Matteo Claudio Da Via, Marta Lionetti, Akihiro Maeda, Silvia Morlupi, Matteo Dugo, Katia Todoerti, Stefania Oliva, Mattia D'Agostino, Paolo Corradini, Ola Landgren, Francesco Iorio, Loredana Pettine, Alessandra Pompa, Martina Manzoni, Luca Baldini, Antonino Neri, Francesco Maura, Niccolò Bolli,

<h4>Purpose</h4>Multiple Myeloma (MM) is a biologically heterogenous plasma-cell disorder. In this study we aimed at dissecting the functional impact on transcriptome of gene mutations, copy-number abnormalities (CNAs), and chromosomal rearrangements (CRs). Moreover, we applied a geno-transcriptomic approach to identify specific biomarkers for personalized treatments.<h4>Methods</h4>We analyzed 514 newly-diagnosed patients from the ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.

Kei Mizuno, Takayuki Sumiyoshi, Takatsugu Okegawa, Naoki Terada, Satoshi Ishitoya, Yu Miyazaki, Takahiro Kojima, Hiromichi Katayama, Naohiro Fujimoto, Shingo Hatakeyama, Masaki Shiota, Koji Yoshimura, Yoshiyuki Matsui, Shintaro Narita, Hiroaki Matsumoto, Ryoma Kurahashi, Hidenori Kanno, Katsuhiro Ito, Hiroko Kimura, Yuki Kamiyama, Takuro Sunada, Takayuki Goto, Takashi Kobayashi, Hitoshi Yamada, Norihiko Tsuchiya, Tomomi Kamba, Hideyasu Matsuyama, Tomonori Habuchi, Masatoshi Eto, Chikara Ohyama, Akihiro Ito, Hiroyuki Nishiyama, Hiroshi Okuno, Toshiyuki Kamoto, Akihiro Fujimoto, Osamu Ogawa, Shusuke Akamatsu,

<h4>Purpose</h4>Although cell-free DNA (cfDNA) testing is expected to drive cancer precision medicine, little is known about the significance of detecting low-frequency variants in circulating cell-free tumor DNA (ctDNA) in castration-resistant prostate cancer (CRPC). We aimed to identify genomic profile including low-frequency variants in ctDNA from CRPC patients and investigate the ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



FLT3L release by NK cells enhances response to radioimmunotherapy in preclinical models of HNSCC.

Thomas E Bickett, Michael Knitz, Laurel B Darragh, Shilpa Bhatia, Benjamin Van Court, Jacob Gadwa, Shiv Bhuvane, Miles Piper, Diemmy Nguyen, Hua Tu, Laurel Lenz, Eric T Clambey, Kevin Barry, Sana D Karam,

<h4>Purpose</h4>Natural Killer (NK) cells are type 1 innate lymphoid cells that are known to secrete cytokines and for their role in killing virally infected cells or cancer cells through cytotoxicity. In addition to direct tumor cell killing, NK cells are known to play fundamental roles in the tumor microenvironment through ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma.

Shu Ling Chen, Yubin Xie, Yuhong Cai, Huanjing Hu, Minghui He, Lijuan Liu, Changyi Liao, Yuanqi Wang, Jianping Wang, Xiaoxue Ren, Qianwen Zeng, Hong Peng, Shunli Shen, Shao-Qiang Li, Dongming Li, Jiaming Lai, Baogang Peng, Jian Ren, Ming Kuang, Sui Peng,

<h4>Purpose</h4>Targeted therapy and immunotherapy are transforming the treatment approach for intrahepatic cholangiocarcinoma(ICC). However, little is known about the intertumor heterogeneity(ITH) of multifocal ICC and its impacts on patient response to these treatments. We aimed to characterize the immunogenomic and epigenomic heterogeneity of multifocal ICC to guide treatment decision making.<h4>Experimental design</h4>We ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.

Shannon N Westin, Marilyne Labrie, Jennifer K Litton, Aurora Blucher, Yong Fang, Christopher P Vellano, Joseph R Marszalek, Ningping Feng, Xiaoyan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, TaeBeom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T Soliman, Michael Frumovitz, Kathleen M Schmeler, Amir Jazaeri, Karen H Lu, Rashmi Murthy, Larissa Meyer, Charlotte Sun, Anil K Sood, Robert L Coleman, Gordon B Mills,

<h4>Purpose</h4>Based on strong preclinical rationale, we sought to confirm recommended phase 2 dose for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess molecular markers of response and resistance.<h4>Experimental design</h4>We performed a safety lead in followed by expansion in endometrial, triple negative breast, or ovarian cancers. Olaparib ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic Relevance of Pancreatic Adenocarcinoma Whole-tumor Transcriptomic Subtypes and Components.

Shulin Zhao, Remy Nicolle, Jeremy Augustin, Magali Svrcek, Louis de Mestier, Delphine Le Corre, Daniel Pietrasz, Olivier Caliez, Jerome Cros, Pierre Laurent-Puig, Jean-Baptiste Bachet,

<h4>Purpose</h4>Our team previously defined six quantitative transcriptomic components, and a classification in five subtypes by association of these components. In this study, we compared the robustness of quantitative components and qualitative classifications from different transcriptomic profiling techniques, investigated their clinical relevance and proposed a new prognostic model.<h4>Experimental design</h4>210 patients from ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial.

Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout, Mary Kudsy, Josephine Morris, Valentina Ferrari, In Hwa Um, James Chettle, Farasat Kazmi, Leticia Campo, Alistair Easton, Sebastian Nijman, Michaela Serpi, Stefan Symeonides, Ruth Plummer, David J Harrison, Gareth Bond, Sarah P Blagden,

<h4>Purpose</h4>Nucleoside analogues form the backbone of many therapeutic regimens in oncology and require the presence of intracellular enzymes for their activation. A ProTide is comprised of a nucleoside fused to a protective phosphoramidate cap. ProTides are easily incorporated into cells whereupon the cap is cleaved and a pre-activated nucleoside released. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A Phase 1 Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel using a novel Randomized Continual Reassessment Method for Dose Escalation.

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla, Anthony W Tolcher, Patricia M LoRusso, Joseph Paul Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron Hj Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P Lolkema,

<h4>Purpose</h4>MPS1 kinase inhibitor, BAY 1217389 (BAY) synergizes with paclitaxel. This phase 1 study assessed the combination of BAY with paclitaxel using a novel randomized continuous reassessment method (rCRM) to improve dose determination.<h4>Experimental design</h4>Patients with solid tumors were randomized to receive oral BAY (BID 2‑days‑on/5‑days‑off) with weekly paclitaxel (90 mg/m<sup>2</sup>) or ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman,

<h4>Purpose</h4>Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relapsed/refractory (R/R) MZL.<h4>Experimental design</h4>Patients with R/R MZL were enrolled in the ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer.

Huanjun Wang, Yan Mei, Cheng Luo, Qun Huang, Zifeng Wang, Guan-Ming Lu, Lili Qin, Zhun Sun, Chao-Wen Huang, Zhi-Wen Yang, Junxing Chen, Weiguo Yin, Chao-Nan Qian, Jianming Zeng, Lingwu Chen, Qibin Leng, Yan Guo, Guangshuai Jia,

<h4>Purpose</h4>Bladder cancer (BC) treatment remains a major clinical challenge due to therapy resistance and a high recurrence rate. Profiling intratumor heterogeneity can reveal the molecular mechanism of BC recurrence.<h4>Experimental design</h4>Here, we performed single-cell RNA-seq and ATAC-seq on tumors from 13 patients with low recurrence risk, high recurrence risk and recurrent ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Single-cell profiling reveals metabolic reprogramming as a resistance mechanism in BRAF-mutated multiple myeloma.

Johannes M Waldschmidt, Jake A Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S Nair, Tushara Vijaykumar, Nam Gyu Im, Amy Guillaumet-Adkins, Nitish Chopra, Hannah Stuart, Lillian Budano, Noori Sotudeh, Guangwu Guo, Clemens Grassberger, Andrew J Yee, Jacob P Laubach, Paul G Richardson, Kenneth C Anderson, Noopur S Raje, Birgit Knoechel, Jens G Lohr,

<h4>Purpose</h4>Although remarkably effective in some patients, precision medicine typically induces only transient responses despite initial absence of resistance-conferring mutations. Using <i>BRAF</i>-mutated myeloma as a model for resistance to precision medicine we investigated if <i>BRAF-</i>mutated cancer cells have the ability to ensure their survival by rapidly adapting to BRAF inhibitor treatment.<h4>Experimental ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma.

Lijie Zhai, April Bell, Erik Ladomersky, Kristen L Lauing, Lakshmi Bollu, Brenda Nguyen, Matthew Genet, Miri Kim, Peiwen Chen, Xinlei Mi, Jennifer D Wu, Matthew J Schipma, Brian Wray, John Griffiths, Richard D Unwin, Simon J Clark, Rajesh Acharya, Riyue Bao, Craig Horbinski, Rimas V Lukas, Gary E Schiltz, Derek A Wainwright,

<h4>Purpose</h4>Glioblastoma (GBM) is an incurable primary brain tumor that has not benefited from immunotherapy to-date. Greater than 90% of GBM expresses the tryptophan (Trp) metabolic enzyme, indoleamine 2,3-dioxygenase 1 (IDO). This observation supported the historical hypothesis that IDO suppresses the antitumor immune response solely through a mechanism that requires intratumoral ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.

Corinne Beinat, Chirag B Patel, Tom Haywood, Surya Murty, Lewis Naya, Jessa B Castillo, Samantha T Reyes, Megan Phillips, Pablo Buccino, Bin Shen, Jun Hyung Park, Mary Ellen Koran, Israt S Alam, Michelle L James, Dawn Holley, Kim Halbert, Harsh Gandhi, Joy Q He, Monica Granucci, Eli Johnson, Daniel Dan Liu, Nobuko Uchida, Rahul Sinha, Pauline Chu, Donald E Born, Geoffrey I Warnock, Irving Weissman, Melanie Hayden Gephart, Mohammad Mehdi Khalighi, Tarik F Massoud, Andrei Iagaru, Guido Davidzon, Reena Thomas, Seema Nagpal, Lawrence D Recht, Sanjiv Sam Gambhir,

<h4>Purpose</h4>Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the development, validation, and translation of a novel positron emission tomography (PET) tracer to study PKM2 in GBM. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.

Arta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M Thrash, Ryan C Brennick, Katrina Z Kao, Claire Manuszak, Ryan D Gentzler, Anteneh Tesfaye, Salma K Jabbour, Olatunji B Alese, Osama E Rahma, James M Cleary, Elad Sharon, Harvey J Mamon, May Cho, Howard Streicher, Helen X Chen, Mansoor M Ahmed, Adrian Mariño-Enríquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I Marusina, Alexander A Merleev, Mariano Severgnini, Kathleen L Pfaff, James Lindsay, Jason L Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J Rodig, F Stephen Hodi, Jonathan D Schoenfeld,

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(17):4940]

Cited: 0 times

View full text PDF listing >>



Selected Articles from This Issue.

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(17):4665]

Cited: 0 times

View full text PDF listing >>



Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study.

Sebastian Bauer, Michael C Heinrich, Suzanne George, John R Zalcberg, César Serrano, Hans Gelderblom, Robin L Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren, Patrick Schöffski,

<h4>Purpose</h4>Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in <i>KIT/PDGFRA</i> and are initially responsive to tyrosine kinase inhibitors (TKIs). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase 3 INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Imaging of Cancer γ-Secretase Activity Using an Inhibitor-based PET Probe.

Pengju Nie, Teja Kalidindi, Veronica L Nagle, Xianzhong Wu, Thomas Li, George P Liao, Georgia Frost, Kelly E Henry, Blesida Punzalan, Lukas M Carter, Jason S Lewis, Naga Vara Kishore Pillarsetty, Yue-Ming Li,

<h4>Purpose</h4>Abnormal notch signaling promotes cancer cell growth and tumor progression in various cancers. Targeting γ-secretase, a pivotal regulator in the Notch pathway, has yielded numerous GSIs for clinical investigation in the last two decades. However, GSIs have demonstrated minimal success in clinical trials in part due to the lack of ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N Brown, Britta Weigelt, Jorge S Reis-Filho, Ben H Park, Sara A Hurvitz, Dennis J Slamon, Mothaffar F Rimawi, Valerie M Jansen, Rinath Jeselsohn, C Kent Osborne, Rachel Schiff,

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(17):4939]

Cited: 0 times

View full text PDF listing >>



Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft tissue sarcoma.

Michael B Livingston, Megan H Jagosky, Myra M Robinson, William A Ahrens, Jennifer H Benbow, Carol J Farhangfar, David M Foureau, Deirdre M Maxwell, Emily A Baldrige, Xhevahire Begic, James T Symanowski, Nury M Steuerwald, Colin J Anderson, Joshua C Patt, Jeffrey S Kneisl, Edward S Kim,

<h4>Purpose</h4>Doxorubicin is standard therapy for advanced soft tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity and tolerability in previous advanced STS studies. This study combined pembrolizumab with doxorubicin to assess safety and efficacy in frontline ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.

Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, Daphne L van der Velden, Laurien J Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W J de Leng, Anne M L Jansen, Niven Mehra, Debbie G J Robbrecht, Mariette Labots, Derk Jan A de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E Voest, Henk M W Verheul,

<h4>Purpose</h4>To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with <i>BRCA1/2</i> mutations, regardless of histological tumor type.<h4>Patients and methods</h4>Patients with treatment-refractory <i>BRCA1/2</i> mutated cancer were included for treatment with off-label olaparib 300 mg twice daily until disease progression or unacceptable toxicity. In DRUP, patients with ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0472 s